Karolinska Development
Unshackling itself from its bonds?
Update | 8 February 2017
Karolinska Development
Unshackling itself from its bonds?
Update | 8 February 2017
Share this note
Karolinska Development intends to restructure the convertible bonds, due to mature in December 2019. The proposal would materially strengthen the balance sheet and allow full implementation of the revised investment strategy. Additionally, in our view, it would remove what has been a distraction for management and a major overhang on the share price. Our valuation of Karolinska Development, based on its four main assets, was SEK 473m(SEK9.10 per share) and is placed under review pending the outcome of the offer.
| Year-end: December | 2014 | 2015 | 2016E | 2017E |
| Sales (SEKm) | 5.0 | 2.9 | 2.1 | 2.1 |
| Adj. PBT (SEKm) | (67.2) | (78.2) | (66.8) | (63.6) |
| Net Income (SEKm) | (371.5) | (1,054.7) | (207.9) | (63.6) |
| Adj. EPS (SEK) | (1.4) | (1.5) | (1.3) | (1.2) |
| Cash (SEKm) | 141.3 | 297.2 | 253.7 | 224.3 |
| EBITDA (SEKm) | (61.6) | (43.6) | (28.9) | (30.0) |
Update
8 February 2017
| Price (SEK) | 5.70 |
| Market Cap (SEKm) | 306.0 |
| Enterprise Value (SEKm) | 432.8 |
| Shares in issue | 51.9m |
| 12 month range | 5.25-10.00 |
| Free float | 100% |
| Primary exchange | OMX |
| Other exchanges | N/A |
| Sector | Healthcare |
| Company Code | KDEV |
| Corporate client | Yes |
Company description
Karolinska Development has been successfully transformed into a leading life sciences investment company that is notably active in the Scandinavian region.
Analysts
Mick Cooper PhD
mcooper@trinitydelta.org
+44 (0) 20 3637 5042
Franc Gregori
fgregori@trinitydelta.org
+44 20 3637 5041
Table of Contents
Karolinska Development has made an offer to issue new B shares through a set-off arrangement to its convertible bond holders. The intention is to strengthen its equity position to allow it execute its revised investment strategy, so enabling future investment in promising new companies, as well as maintaining compliance with the Swedish Companies Act (Aktiebolagslagen). The step marks the final stages of the major restructuring that has been underway over the past two years. New management has revitalised the company, with material changes to the investment philosophy, the adoption of a greater commercial outlook, and the creation of a more focussed portfolio.
Karolinska Development has announced its intention to offer to issue new B shares to its convertible bond holders though a set-off arrangement. The voluntary agreement would see the new shares issued at the higher of the VWAP (volume weighted average share price) of the 90 trading day period ending either two trading days prior to the announcement, which is SEK 6.17 per share, or at the two trading days period before the EGM (8th March 2017).
The balance sheet is sound and has funding in place for the known investment and operational needs, with SEK 256.3m in cash and equivalents at September 2016. However, the equity position needs further strengthening to execute on the investment opportunities that are now presenting themselves and to continue to comply with the Swedish Companies Act (Aktiebolagslagen). The full conversion of the bonds would move Karolinska Development from a net debt position of SEK 127m to a net cash position of SEK 256m.
As background, in January 2015 a convertible bond with a nominal amount of SEK 387m was issued. These bonds are listed on Nasdaq Stockholm (ISIN: SE0006510103) and carry an annual interest rate of 8% over a term of 5 years. The outstanding amount, including interest, is approximately SEK 451m as of 31 December 2016. These can be called for conversion into B-shares up until 30 June 2019 at a price of SEK 22.00. Assuming these are held to maturity with the interest accrued, the amount repayable would be SEK 568m with 25.8m new shares issued.
CP Group holds 70.53% of the convertible bonds and a further 9.08% of the equity (representing 7.24% of the votes). These are held indirectly via Sino Biopharmaceutical Limited and its subsidiaries. If CP Group were to set off all of its convertible holdings to B-shares its total holding would exceed the 30% threshold of the voting rights and would be obliged to launch a mandatory bid. CP Group could apply for exception for this requirement but whether this will be done or would be allowed by the Swedish Securities Council is as yet unknown.
A number of scenarios could arise. If all convertible holders accept the offer, this would result in a set-off of SEK 451m of the outstanding convertible debt and CP Group would hold 44.58% of the capital and 40.27% of the voting rights. If CP Group were the only convertible holder to accept the offer, this results in a set-off of SEK 318m of the outstanding convertible debt and CP Group would hold 53.72% of the capital and 47.59% of the voting rights.
If CP Group were to keep their holding just below the 30% threshold and assuming that all other convertible holders accept the offer, the maximum amount that can be set off will be SEK 324m. If CP Group were the only convertible holder to accept the offer and wants to keep their holding below the 30% threshold the maximum amount that can be set off will be SEK 134m.
The offer is subject to shareholder approval and an EGM is scheduled for 8th March 2017, with a two thirds majority required. If all convertible holders were to accept the offer a maximum of 73.1m new B shares would be issued (based on SEK6.17 per share), with a corresponding dilution of 58% for the B shares and 52% for the voting rights. If the resolution does not pass, the convertible debt, with an exercise price of SEK22 per share and value of SEK 568m, would have to be repaid in December 2019.
We have placed our valuation under review pending the result of the EGM and the outcome of the proposed conversion. We previously valued Karolinska Development at SEK 473m (equivalent to SEK9.10 a share). We employ a sum-of-the-parts valuation of its four leading investments (Aprea, OssDsign, Modus Therapeutics, and Promimic), which are valued using DCF-based methods, including rNPV models for the biotech investments and three-phase DCF valuations for those with marketed products.
We have examined the possible impact on the proposed debt to equity conversion and have detailed four potential scenarios in Exhibit 2. The likely outcome is particularly difficult to assess, with the number of variables greater than is typical in such cases (notably whether CP Group will seek exception from the mandatory 30% threshold and whether the Swedish Securities Council will grant it), nonetheless the scenarios used do provide a useful point of reference.
Scenario 1 provides the existing situation and Scenario 4 examines the outcome if all of the convertible bonds where to be exercised in the set off process. Whilst these set the boundaries, the most likely outcome will probably lie somewhere between Scenarios 2 and 3 and so are representative of the potential impact. It is worth noting that whilst existing shareholder dilution is inevitable, in all conversion scenarios our numbers suggest that there remains upside against the current share price.
Disclaimer
Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.
ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.
In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.
Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.
This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.
Copyright 2017 Trinity Delta Research Limited. All rights reserved.